- Viatris will pay Pacira investors $36.50 per share in cash, a 45% premium over Wednesday's closing price, for an aggregate equity value of $1.65 billion; the transaction is expected to close by the end of 2026.
- The deal hands Viatris two non-opioid pain treatments, Exparel for post-surgical pain and Zilretta for knee osteoarthritis pain, which booked $692 million in sales in 2025, up about 4% over 2024.
- Generic erosion of Exparel is likely to begin in early 2030 under patent settlements Pacira struck with Fresenius Kabi and a Hengrui Pharma subsidiary, which allow the two to market high single digit percentages of US volume escalating toward the 30% range within three years.
- Leerink analyst Daniel Clark wrote that the transaction should be immediately accretive to revenue and help grow earnings into the 2030s, calling it consistent with Viatris' strategy of purchasing on-market, commercial assets.
Quotes
“expects to expand the products' reach across select markets within its global infrastructure”
“purchasing on-market, commercial assets”
“plans to leverage its intellectual property expertise and proven ability to extend product lifecycles and sustain meaningful sales”